cd20 antigens การใช้

• Rituxan works by binding to a protein known as the CD20 antigen on the surface of mature B cells and B-cell tumors.
• AME-133v is a humanized IgG1 monoclonal antibody targeting the CD20 antigen on both healthy and malignant B-lymphocytes, engineered at Applied Molecular Evolution.
• Because stem cells present in the bone marrow lack the CD20 antigen they are not affected by the drug, and in clinical studies returned to normal levels within several months of the completion of treatment.
• The antibody is engineered for enhanced affinity to the CD20 antigen on B-lymphocytes, increased antibody-dependent cell-mediated cytotoxicity ( ADCC ), and for improved treatment of low-affinity Fc?RIIIa allotypes.